Extracellular ATP/P2X7 Receptor, a Regulatory Axis of Migration in Ovarian Carcinoma-derived Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jun 13

PMID 38870128

Authors

Jose David Nunez-Rios

Mauricio Reyna-Jeldes

Esperanza Mata-Martinez

Anai Del Rocio Campos-Contreras

Ivan Lazcano-Sanchez

Adriana Gonzalez-Gallardo

Mauricio Diaz-Munoz

Claudio Coddou

Francisco G Vazquez-Cuevas

Affiliations

Soon will be listed here.

Abstract

ATP is actively maintained at high concentrations in cancerous tissues, where it promotes a malignant phenotype through P2 receptors. In this study, we first evaluated the effect of extracellular ATP depletion with apyrase in SKOV-3, a cell line derived from metastatic ovarian carcinoma. We observed a decrease in cell migration and an increase in transepithelial electrical resistance and cell markers, suggesting a role in maintaining a mesenchymal phenotype. To identify the P2 receptor that mediated the effects of ATP, we compared the transcript levels of some P2 receptors and found that P2RX7 is three-fold higher in SKOV-3 cells than in a healthy cell line, namely HOSE6-3 (from human ovarian surface epithelium). Through bioinformatic analysis, we identified a higher expression of the P2RX7 transcript in metastatic tissues than in primary tumors; thus, P2X7 seems to be a promising effector for the malignant phenotype. Subsequently, we demonstrated the presence and functionality of the P2X7 receptor in SKOV-3 cells and showed through pharmacological approaches that its activity promotes cell migration and contributes to maintaining a mesenchymal phenotype. P2X7 activation using BzATP increased cell migration and abolished E-cadherin expression. On the other hand, a series of P2X7 receptor antagonists (A438079, BBG and OxATP) decreased cell migration. We used a CRISPR-based knock-out system directed to P2RX7. According to the results of our wound-healing assay, SKOV3-P2X7KO cells lacked receptor-mediated calcium mobilization and decreased migration. Altogether, these data let us propose that P2X7 receptor is a regulator for cancer cell migration and thus a potential drug target.

References

Di Virgilio F . Purines, purinergic receptors, and cancer. Cancer Res. 2012; 72(21):5441-7. DOI: 10.1158/0008-5472.CAN-12-1600. View

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

Cammareri P, Myant K . Be like water, my cells: cell plasticity and the art of transformation. Front Cell Dev Biol. 2023; 11:1272730. PMC: 10598658. DOI: 10.3389/fcell.2023.1272730. View

Campos-Contreras A, Gonzalez-Gallardo A, Diaz-Munoz M, Vazquez-Cuevas F . Adenosine Receptor A2B Negatively Regulates Cell Migration in Ovarian Carcinoma Cells. Int J Mol Sci. 2022; 23(9). PMC: 9100769. DOI: 10.3390/ijms23094585. View

Giannuzzo A, Pedersen S, Novak I . The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer. 2015; 14:203. PMC: 4660609. DOI: 10.1186/s12943-015-0472-4. View

Cormio G, Maneo A, Parma G, Pittelli M, Miceli M, Bonazzi C . Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. Ann Oncol. 1995; 6(6):571-4. DOI: 10.1093/oxfordjournals.annonc.a059246. View

Qiu Y, Li W, Zhang H, Liu Y, Tian X, Fang W . P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One. 2014; 9(12):e114371. PMC: 4259308. DOI: 10.1371/journal.pone.0114371. View

Arnaud-Sampaio V, Rabelo I, Ulrich H, Lameu C . The P2X7 Receptor in the Maintenance of Cancer Stem Cells, Chemoresistance and Metastasis. Stem Cell Rev Rep. 2019; 16(2):288-300. DOI: 10.1007/s12015-019-09936-w. View

Mohammed A, Janakiram N, Madka V, Pathuri G, Li Q, Ritchie R . Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Oncotarget. 2017; 8(58):97822-97834. PMC: 5716694. DOI: 10.18632/oncotarget.22085. View

10.

Tan D, Agarwal R, Kaye S . Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006; 7(11):925-34. DOI: 10.1016/S1470-2045(06)70939-1. View

11.

Hattori M, Gouaux E . Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012; 485(7397):207-12. PMC: 3391165. DOI: 10.1038/nature11010. View

12.

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F . Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008; 3(7):e2599. PMC: 2440522. DOI: 10.1371/journal.pone.0002599. View

13.

Martinez-Ramirez A, Diaz-Munoz M, Butanda-Ochoa A, Vazquez-Cuevas F . Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT). Purinergic Signal. 2016; 13(1):1-12. PMC: 5334205. DOI: 10.1007/s11302-016-9550-3. View

14.

Feng Y, Li X, Wang L, Zhou L, Gorodeski G . A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem. 2006; 281(25):17228-17237. PMC: 2409001. DOI: 10.1074/jbc.M602999200. View

15.

Chen K, Yuan X, Wang S, Zheng F, Fu Z, Shen Z . MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage. Oncogene. 2023; 42(18):1438-1452. PMC: 10154218. DOI: 10.1038/s41388-023-02650-5. View

16.

Bai X, Li Q, Peng X, Li X, Qiao C, Tang Y . P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways. Purinergic Signal. 2023; 19(4):685-697. PMC: 10754800. DOI: 10.1007/s11302-023-09928-z. View

17.

Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A . The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2021; 50(D1):D687-D692. PMC: 8689983. DOI: 10.1093/nar/gkab1028. View

18.

Park M, Kim J, Phuong N, Park J, Park J, Kim Y . Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production. Sci Rep. 2019; 9(1):11587. PMC: 6690963. DOI: 10.1038/s41598-019-47734-z. View

19.

Santos Jr A, Cappellari A, de Marchi F, Gehring M, Zaparte A, Brandao C . Potential role of P2X7R in esophageal squamous cell carcinoma proliferation. Purinergic Signal. 2017; 13(3):279-292. PMC: 5563289. DOI: 10.1007/s11302-017-9559-2. View

20.

Slater M, Danieletto S, Gidley-Baird A, Teh L, Barden J . Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology. 2004; 44(3):206-15. DOI: 10.1111/j.0309-0167.2004.01798.x. View